Cheri Blacksten, MD
Family Medicine · Albuquerque, NMNPI 1124254586
Payments from drug & device makers
Across 495 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$978
- AbbVie$941
- Lilly USA, LLC$670
- Pfizer$421
- Takeda Pharmaceuticals U.S.A., Inc.$298
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,13024%
- Food & beverage$6,91776%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 129 | $3,332 |
| AstraZeneca | 39 | $978 |
| AbbVie(2 entities) | 89 | $941 |
| Lilly USA, LLC | 40 | $670 |
| Pfizer | 22 | $421 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $298 |
| GSK | 17 | $257 |
| Nestle Healthcare Nutrition Inc. | 17 | $240 |
| Boehringer Ingelheim | 14 | $229 |
| Amgen | 13 | $203 |
| Amarin Pharma, Inc. | 20 | $193 |
| Daiichi Sankyo Inc. | 7 | $137 |
| Exact Sciences | 7 | $123 |
| Organon | 13 | $123 |
| Sanofi Pasteur Inc. | 5 | $114 |
| Novartis | 6 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Inspire Medical Systems, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 2 | $59 |
| Biohaven Pharmaceuticals, Inc. | 4 | $55 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Merck | 2 | $33 |
| Abbott | 2 | $28 |
| Radius Health, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 2 | $24 |
| Eisai Inc. | 1 | $22 |
| Neuronetics, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Coopersurgical, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,047 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $42,501 |
| TrulicityDulaglutide | 32 | $37,168 |
| OzempicSemaglutide | 22 | $28,923 |
| MounjaroTirzepatide | 27 | $28,729 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $23,424 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $19,112 |
| XareltoRivaroxaban | 14 | $18,150 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $3,248 |
| Estradiol | 19 | $1,735 |
| Gabapentin | 62 | $1,711 |
| Atorvastatin Calcium | 123 | $1,704 |
| Levothyroxine Sodium | 111 | $1,693 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,599 |
| Rosuvastatin Calcium | 58 | $1,299 |
| Tamsulosin Hcl | 33 | $1,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $670 | $65,89859 claims |
| AstraZenecaFarxiga | $978 | $42,50152 claims |
| Novo NordiskOzempic | $3,332 | $28,92322 claims |
| Boehringer IngelheimStiolto Respimat | $229 | $23,42433 claims |
| GSKTrelegy Ellipta | $257 | $19,11218 claims |
| Johnson & JohnsonXarelto | $12 | $18,15014 claims |
| AbbVieSynthroid | $941 | $67822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Albuquerque
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
- Sally FisherAlbuquerque$1.8M
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Timothy GrenemyerAlbuquerque$10K
- Michael MontoyaAlbuquerque$7K
- Yvonne Vanarsdale-ImaniAlbuquerque$7K
- Donald OrtizAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.